The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer.
Avani Atul Shah
No relevant relationships to disclose
Fatima Karzai
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
Cindy H. Chau
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Guinevere Chun
No relevant relationships to disclose
John Joseph Wright
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
Howard L. Parnes
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose